Yesterday, Samumed’s CEO Dr. Osman Kibar gave an interesting interview to Fierce Biotech (h/t reader “John Doe”). The most relevant part of this interview for us is:
“Its alopecia treatment is close behind, with approval anticipated in late 2021 or early 2022.”
Not a surprise as far as time frame goes, but Mr. Kibar seems confident that they will get approval. I am assuming he agreed with the above sentence in the interview or was quoted as such.
Not sure if other CEOs “anticipate” approval chances before Phase 3 trials are complete. I am hoping that Samumed has seen good results during the first year of ongoing Phase 3 trials in order to warrant this confidence.
The interview also has some interesting information about the scientific reasoning behind why Samumed’s products are safe despite targeting the critical Wnt pathway.
For those of us who have been following hair loss cure research for the past half decade, the number one person of interest is Japan’s Dr. Takashi Tsuji. He has previously announced that he is going to release a cure for hair loss in 2020.
Recently, a Japanese hair enthusiast named “Youngjet” posted a video regarding his attendance of a recent lecture in Japan by Dr. Tsuji. Five people emailed me or commented on here about the below video!
After you translate the video, it seems like Dr. Tsuji will release his cure in 2020 and/or 2021. It will initially cost 20 million to 40 million Japanese Yen ($190,000 – $380,000 per today’s exchange rates). Prices will then slowly come down over the next decade.
Perhaps Dr. Tsuji gave us two numbers (20 million and 40 million) because some people will have one session and some will have two sessions?
Note that as of 2019, they are already testing this treatment in humans. Favorable Japanese regulations probably allow for this possibility, even though clinical trials are yet to be completed.